Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorİnan, Sibel
dc.contributor.authorBaysal, Zeki
dc.contributor.authorİnan, Ümit Übeyt
dc.date.accessioned2021-05-05T22:11:51Z
dc.date.available2021-05-05T22:11:51Z
dc.date.issued2020
dc.identifier.issn0271-3683
dc.identifier.urihttps://doi.org/10.1080/02713683.2019.1675174
dc.identifier.urihttps://hdl.handle.net/20.500.12933/179
dc.descriptionPubMed: 31581852en_US
dc.description2-s2.0-85074020039en_US
dc.description.abstractDear Editor, We appreciate the letter from Kai Xiong Cheong and Colin S. Tan regarding our study “Long-term changes in submacular choroidal thickness after treatment for neovascular age-related macular degeneration”.1 We thank colleagues Cheong and Tan for sharing their experience on this topic.2,3 They addressed several issues that are important in the studies of choroidal thickness (CT) measurement. We agree mostly with this comment; however, we need to explain some issues taking place methodologically in our study.en_US
dc.language.isoengen_US
dc.publisherTaylor and Francis Ltden_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChoroidal thicknessen_US
dc.subjectdiurnal variationen_US
dc.subjectneovascular age-related macular degenerationen_US
dc.subjectranibizumaben_US
dc.subjecttopographic variationen_US
dc.titleLong-Term Changes in Submacular Choroidal Thickness after Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 14-Mo Follow-Upen_US
dc.typeletteren_US
dc.departmentAFSÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göz Hastalıkları Ana Bilim Dalı
dc.contributor.institutionauthorİnan, Sibel
dc.identifier.doi10.1080/02713683.2019.1675174
dc.identifier.volume45en_US
dc.identifier.issue4en_US
dc.identifier.startpage527en_US
dc.identifier.endpage528en_US
dc.relation.journalCurrent Eye Researchen_US
dc.relation.publicationcategoryDiğeren_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster